» Articles » PMID: 31991775

The "Janus Face" of Platelets in Cancer

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2020 Jan 30
PMID 31991775
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Besides their vital role in hemostasis and thrombosis, platelets are also recognized to be involved in cancer, where they play an unexpected central role: They actively influence cancer cell behavior, but, on the other hand, platelet physiology and phenotype are impacted by tumor cells. The existence of this platelet-cancer loop is supported by a large number of experimental and human studies reporting an association between alterations in platelet number and functions and cancer, often in a way dependent on patient, cancer type and treatment. Herein, we shall report on an update on platelet-cancer relationships, with a particular emphasis on how platelets might exert either a protective or a deleterious action in all steps of cancer progression. To this end, we will describe the impact of (i) platelet count, (ii) bioactive molecules secreted upon platelet activation, and (iii) microvesicle-derived miRNAs on cancer behavior. Potential explanations of conflicting results are also reported: Both intrinsic (heterogeneity in platelet-derived bioactive molecules with either inhibitory or stimulatory properties; features of cancer cell types, such as aggressiveness and/or tumour stage) and extrinsic (heterogeneous characteristics of cancer patients, study design and sample preparation) factors, together with other confounding elements, contribute to "the Janus face" of platelets in cancer. Given the difficulty to establish the univocal role of platelets in a tumor, a better understanding of their exact contribution is warranted, in order to identify an efficient therapeutic strategy for cancer management, as well as for better prevention, screening and risk assessment protocols.

Citing Articles

Exploring cell-derived extracellular vesicles in peripheral blood and bone marrow of B-cell acute lymphoblastic leukemia pediatric patients: proof-of-concept study.

Magalhaes-Gama F, Malheiros Araujo Silvestrini M, Neves J, Araujo N, Alves-Hanna F, Kerr M Front Immunol. 2024; 15:1421036.

PMID: 39234258 PMC: 11371606. DOI: 10.3389/fimmu.2024.1421036.


Pre-treatment thrombocytosis and ovarian cancer survival: A meta-analysis.

Pergialiotis V, Vogiatzi Vokotopoulou L, Vlachos D, Liontos M, Kontomanolis E, Thomakos N Eur J Obstet Gynecol Reprod Biol X. 2024; 22:100312.

PMID: 38745890 PMC: 11091518. DOI: 10.1016/j.eurox.2024.100312.


Synthesis of Novel Nilotinib Analogues and Biological Evaluation of Their Antiplatelet Activity and Functionality towards Cancer Cell Proliferation In Vitro.

Pechlivani L, Ntemou N, Pantazi D, Alivertis D, Skobridis K, Tselepis A Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543136 PMC: 10974042. DOI: 10.3390/ph17030349.


Tumor cell-induced platelet aggregation accelerates hematogenous metastasis of malignant melanoma by triggering macrophage recruitment.

Chen Y, Zhou J, Liu Z, Wu T, Li S, Zhang Y J Exp Clin Cancer Res. 2023; 42(1):277.

PMID: 37872588 PMC: 10591353. DOI: 10.1186/s13046-023-02856-1.


Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment.

Canto E, Anguera G, Jimenez N, Mellado B, Ramirez O, Mariscal A Diagnostics (Basel). 2023; 13(13).

PMID: 37443615 PMC: 10340498. DOI: 10.3390/diagnostics13132222.


References
1.
Reddel C, Tan C, Chen V . Thrombin Generation and Cancer: Contributors and Consequences. Cancers (Basel). 2019; 11(1). PMC: 6356447. DOI: 10.3390/cancers11010100. View

2.
Biino G, Santimone I, Minelli C, Sorice R, Frongia B, Traglia M . Age- and sex-related variations in platelet count in Italy: a proposal of reference ranges based on 40987 subjects' data. PLoS One. 2013; 8(1):e54289. PMC: 3561305. DOI: 10.1371/journal.pone.0054289. View

3.
Shimada H, Oohira G, Okazumi S, Matsubara H, Nabeya Y, Hayashi H . Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg. 2004; 198(5):737-41. DOI: 10.1016/j.jamcollsurg.2004.01.022. View

4.
Dirix L, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P . Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer. 2002; 86(3):389-95. PMC: 2375200. DOI: 10.1038/sj.bjc.6600069. View

5.
Lee M, Kim S, Nam E, Yim G, Kim S, Kim Y . The impact of pretreatment thrombocytosis and persistent thrombocytosis after adjuvant chemotherapy in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 2011; 122(2):238-41. DOI: 10.1016/j.ygyno.2011.04.012. View